Dihydromyricetin alleviates attention deficit hyperactivity disorder by modulating the SIRT1/Nrf2/Keap1/HO-1 signaling pathway

Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, with limited effective treatments available. This study investigated the therapeutic potential of Dihydromyricetin (DMY) in a monosodium glutamate (MSG)-induced ADHD mouse model. Behavioral tests, including open field, Y-maze, and social interaction tests, were conducted to assess hyperactivity, attention, and social behavior. Molecular…

via https://pubmed.ncbi.nlm.nih.gov/41366813/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20251222010906&v=2.18.0.post22+67771e2